BASEL, SWITZERLAND – BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company focused on novel antibacterial products for multi-drug resistant (MDR) infections, announced the results of its Annual General Meeting (AGM) held on April 30, 2026. All proposals by the Board of Directors were approved by shareholders, reflecting strong support for the company’s strategic direction.
Key resolutions included the acceptance of the 2025 Annual Report and financial statements, re-election of Seng Chin Mah as Chairman, and re-election of board members David Hunstad, Marc Gitzinger, Marina von Schonau, and Ulrik Schulze. Simona Skerjanec was elected as a new member of the Board of Directors. Shareholders also approved compensation packages for the board and executive committee for upcoming terms.
Dr. Seng Chin Mah, Chairman, expressed gratitude for shareholder trust and highlighted the company’s focus on the global Phase 3 trial for BV100, a treatment for Acinetobacter baumannii infections, and progress on alpibectir for tuberculosis in collaboration with GSK. The meeting acknowledged the contributions of outgoing board member Dr. William Jenkins.
The company’s pipeline targets serious MDR infections using its TRIC and Ansamycin Chemistry platforms. Detailed meeting documents are available on the company’s website: Annual Report and AGM Materials.
BioVersys is based in Basel, Switzerland, and continues to advance its pipeline to address high unmet medical needs in antimicrobial and microbiome fields.
